Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple Myeloma
NCT06223646 is registered in ClinicalTrials.gov with Novatim Immune Therapeutics (Zhejiang) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 11, 2024
- Completion date
- March 31, 2026
- Enrollment
- 29 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.